{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:12Z","timestamp":1781513712324,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05092-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:58:43Z","timestamp":1772193523000},"page":"11963-11973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety of voretigene neparvovec: a disproportionality analysis for signal detection using the FAERS database"],"prefix":"10.1007","volume":"399","author":[{"given":"Pengyue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"6","key":"5092_CR1","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ymthe.2005.08.008","volume":"12","author":"GM Acland","year":"2005","unstructured":"Acland GM, Aguirre GD, Bennett J et al (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12(6):1072\u20131082. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.008","journal-title":"Mol Ther"},{"issue":"4","key":"5092_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"5092_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2021","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD (2021) Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety. Prog Retin Eye Res 83:100915. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100915","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"5092_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","volume":"38","author":"BFM Castro","year":"2024","unstructured":"Castro BFM, Steel JC, Layton CJ (2024) AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies. BioDrugs\u202f: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 38(1):73\u201393. https:\/\/doi.org\/10.1007\/s40259-023-00629-y","journal-title":"BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"5092_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.omtm.2021.05.011","volume":"22","author":"LC Chandler","year":"2021","unstructured":"Chandler LC, McClements ME, Yusuf IH, de la Martinez-Fernandez Camara C, MacLaren RE, Xue K (2021) Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina. Mol Ther Methods Clin Dev 22:52\u201365. https:\/\/doi.org\/10.1016\/j.omtm.2021.05.011","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"5092_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-021-00180-1","volume":"6","author":"TC Chen","year":"2021","unstructured":"Chen TC, Huang DS, Lin CW et al (2021) Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan. NPJ Genom Med 6(1):3. https:\/\/doi.org\/10.1038\/s41525-021-00180-1","journal-title":"NPJ Genom Med"},{"issue":"5","key":"5092_CR7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng C, Zhao PY, Branham K et al (2022) Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie 260(5):1543\u20131550. https:\/\/doi.org\/10.1007\/s00417-021-05508-2","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie"},{"issue":"3","key":"5092_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]. Am Stat 53(3):177\u2013190","journal-title":"Am Stat"},{"issue":"6","key":"5092_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5092_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010122","author":"MD Fischer","year":"2024","unstructured":"Fischer MD, Simonelli F, Sahni J et al (2024) Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE Study. Biomolecules. https:\/\/doi.org\/10.3390\/biom14010122","journal-title":"Biomolecules"},{"issue":"1","key":"5092_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-1-40","volume":"1","author":"C Hamel","year":"2006","unstructured":"Hamel C (2006) Retinitis pigmentosa. Orphanet J Rare Dis 1(1):40. https:\/\/doi.org\/10.1186\/1750-1172-1-40","journal-title":"Orphanet J Rare Dis"},{"issue":"1-2","key":"5092_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/jop.2017.0121","volume":"34","author":"RR Hartman","year":"2018","unstructured":"Hartman RR, Kompella UB (2018) Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery. Journal of Ocular Pharmacology and Therapeutics\u202f: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 34(1\u20132):141\u2013153. https:\/\/doi.org\/10.1089\/jop.2017.0121","journal-title":"Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics"},{"key":"5092_CR13","doi-asserted-by":"publisher","unstructured":"Hu K, Jin L, Zhou Y, Xie G. Pharmacologically induced autoimmune encephalitis-disproportionality analysis utilizing FAERS database. Expert Opin Drug Saf. Dec 27 2024:1\u20139. https:\/\/doi.org\/10.1080\/14740338.2024.2446425","DOI":"10.1080\/14740338.2024.2446425"},{"key":"5092_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom13101484","author":"P Kiraly","year":"2023","unstructured":"Kiraly P, Cottriall CL, Taylor LJ et al (2023) Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules. https:\/\/doi.org\/10.3390\/biom13101484","journal-title":"Biomolecules"},{"issue":"4","key":"5092_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.survophthal.2004.04.003","volume":"49","author":"RK Koenekoop","year":"2004","unstructured":"Koenekoop RK (2004) An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol 49(4):379\u2013398. https:\/\/doi.org\/10.1016\/j.survophthal.2004.04.003","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"5092_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1442-9071.2007.01534.x","volume":"35","author":"RK Koenekoop","year":"2007","unstructured":"Koenekoop RK, Lopez I, den Hollander AI, Allikmets R, Cremers FP (2007) Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Exp Ophthalmol 35(5):473\u2013485. https:\/\/doi.org\/10.1111\/j.1442-9071.2007.01534.x","journal-title":"Clin Exp Ophthalmol"},{"key":"5092_CR17","first-page":"52","volume":"12","author":"MK Lin","year":"2015","unstructured":"Lin MK, Tsai YT, Tsang SH (2015) Emerging treatments for retinitis pigmentosa: genes and stem cells, as well as new electronic and medical therapies, are gaining ground. Retinal Physician 12:52\u201370","journal-title":"Retinal Physician"},{"issue":"9","key":"5092_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA et al (2019) Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126(9):1273\u20131285. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.017","journal-title":"Ophthalmology"},{"issue":"3","key":"5092_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/iio.0000000000000366","volume":"61","author":"N Mehta","year":"2021","unstructured":"Mehta N, Robbins DA, Yiu G (2021) Ocular inflammation and treatment emergent adverse events in retinal gene therapy. Int Ophthalmol Clin 61(3):151\u2013177. https:\/\/doi.org\/10.1097\/iio.0000000000000366","journal-title":"Int Ophthalmol Clin"},{"issue":"2-3","key":"5092_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/21678707.2020.1735352","volume":"8","author":"M Menghini","year":"2020","unstructured":"Menghini M, Cehajic-Kapetanovic J, MacLaren RE (2020) Monitoring progression of retinitis pigmentosa: current recommendations and recent advances. Expert Opin Orphan Drugs 8(2\u20133):67\u201378. https:\/\/doi.org\/10.1080\/21678707.2020.1735352","journal-title":"Expert Opin Orphan Drugs"},{"issue":"6","key":"5092_CR21","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1073\/pnas.95.6.3088","volume":"95","author":"H Morimura","year":"1998","unstructured":"Morimura H, Fishman GA, Grover SA, Fulton AB, Berson EL, Dryja TP (1998) Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A 95(6):3088\u20133093. https:\/\/doi.org\/10.1073\/pnas.95.6.3088","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"5092_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10097","key":"5092_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/s0140-6736(17)31868-8","journal-title":"Lancet"},{"key":"5092_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101115","volume":"92","author":"K Stingl","year":"2023","unstructured":"Stingl K, Kempf M, Jung R et al (2023) Therapy with voretigene neparvovec. How to measure success? Prog Retin Eye Res 92:101115. https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101115","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"5092_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ajo.2007.08.022","volume":"144","author":"EM Stone","year":"2007","unstructured":"Stone EM (2007) Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 144(6):791\u2013811. https:\/\/doi.org\/10.1016\/j.ajo.2007.08.022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5092_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4103\/1673-5374.375319","volume":"19","author":"R Sulak","year":"2024","unstructured":"Sulak R, Liu X, Smedowski A (2024) The concept of gene therapy for glaucoma: the dream that has not come true yet. Neural Regen Res 19(1):92\u201399. https:\/\/doi.org\/10.4103\/1673-5374.375319","journal-title":"Neural Regen Res"},{"issue":"13-14","key":"5092_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/hum.2023.191","volume":"35","author":"J Vendom\u00e8le","year":"2024","unstructured":"Vendom\u00e8le J, Chauveau GA, Dalkara D, Galy A, Fisson S (2024) Peripheral cellular immune responses induced by subretinal adeno-associated virus gene transfer can be restrained by the subretinal-associated immune inhibition mechanism. Hum Gene Ther 35(13\u201314):464\u2013476. https:\/\/doi.org\/10.1089\/hum.2023.191","journal-title":"Hum Gene Ther"},{"issue":"1","key":"5092_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.18773\/austprescr.2021.067","volume":"45","author":"Voretigene neparvovec for inherited retinal dystrophy","year":"2022","unstructured":"Voretigene neparvovec for inherited retinal dystrophy (2022) Aust Prescr 45(1):33. https:\/\/doi.org\/10.18773\/austprescr.2021.067","journal-title":"Aust Prescr"},{"issue":"11","key":"5092_CR29","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/14740338.2024.2322712","volume":"23","author":"X Xiong","year":"2024","unstructured":"Xiong X, Zhang X, Li X, Huang T (2024) Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf 23(11):1447\u20131452. https:\/\/doi.org\/10.1080\/14740338.2024.2322712","journal-title":"Expert Opin Drug Saf"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05092-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05092-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05092-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:20:57Z","timestamp":1781511657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05092-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5092"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05092-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in the study are secondhand, coming from public databases. Ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}